Interleukin-5 Antagonist class drugs
2 results
Cinqair (reslizumab)
(Reslizumab)Teva Respiratory, LLC
Usage: CINQAIR® is indicated as add-on maintenance treatment for adults aged 18 and older with severe asthma having an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.
Nucala (mepolizumab)
(mepolizumab)GlaxoSmithKline LLC
Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma with eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients 12 years and older. It is not for acute bronchospasm relief.